4.5 Article

Everyday Function in Alzheimer's and Parkinson's Patients with Mild Cognitive Impairment

期刊

JOURNAL OF ALZHEIMERS DISEASE
卷 79, 期 1, 页码 197-209

出版社

IOS PRESS
DOI: 10.3233/JAD-200256

关键词

Activities of daily living; Alzheimer's disease; cognitive dysfunction; dementia; mild cognitive impairment; Parkinson's disease

资金

  1. Janssen Research and Development, a division of Janssen Pharmaceutica N.V
  2. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01AG024904]
  3. DODADNI (Department of Defense) [W81XWH-12-2-0012]
  4. National Institute on Aging
  5. National Institute of Biomedical Imaging and Bioengineering
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica, Inc.
  11. Biogen
  12. BristolMyers Squibb Company
  13. CereSpir, Inc.
  14. Cogstate
  15. Eisai Inc.
  16. Elan Pharmaceuticals, Inc.
  17. Eli Lilly and Company
  18. EuroImmun
  19. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  20. Fujirebio
  21. GE Healthcare
  22. IXICO Ltd.
  23. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  24. Johnson & Johnson Pharmaceutical Research & Development LLC.
  25. NeuroRx Research
  26. Neurotrack Technologies
  27. Novartis Pharmaceuticals Corporation
  28. Pfizer Inc.
  29. Piramal Imaging
  30. Servier
  31. Takeda Pharmaceutical Company
  32. Transition Therapeutics
  33. Canadian Institutes of Health Research
  34. Lumosity
  35. Lundbeck
  36. Merck Co., Inc.
  37. Meso Scale Diagnostics, LLC.

向作者/读者索取更多资源

Through FAQ assessment, it was found that PD-MCI patients had more difficulties with tax records and traveling, while AD-MCI patients were more impaired in managing finances and remembering appointments. The classification accuracy of the FAQ differed between MCI related to PD and AD.
Background: Instrumental activities of daily living (IADL) impairment can begin in mild cognitive impairment (MCI), and is the core criteria for diagnosing dementia in both Alzheimer's (AD) and Parkinson's (PD) diseases. The Functional Activities Questionnaire (FAQ) has high discriminative power for dementia and MCI in older age populations, but is influenced by demographic factors. It is currently unclear whether the FAQ is suitable for assessing cognitive-associated IADL in non-demented PD patients, as motor disorders may affect ratings. Objective: To compare IADL profiles in MCI patients with PD (PD-MCI) and AD (AD-MCI) and to verify the discriminative ability of the FAQ for MCI in patients with (PD-MCI) and without (AD-MCI) additional motor impairment. Methods: Data of 42 patients each of PD-MCI, AD-MCI, PD cognitively normal (PD-CN), and healthy controls (HC), matched according to age, gender, education, and global cognitive impairment were analyzed. ANCOVA and binary regressions were used to examine the relationship between the FAQ scores and groups. FAQ cut-offs for PD-MCI (versus PD-NC) and AD-MCI (versus HC) were separately identified using receiver operating characteristic analyses. Results: FAQ total score did not differentiate between MCI groups. PD-MCI subjects had greater difficulties with tax records and traveling while AD-MCI individuals were more impaired in managing finances and remembering appointments. Classification accuracy of the FAQ was good for diagnosing AD-MCI (69%, cut-off >= 1) compared to HC, and sufficient for differentiating PD-MCI (38.1%, cut-off >= 3) from PD-CN. Conclusion: The FAQ task profiles and classification accuracy differed between MCI related to PD and AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据